Cure8 research brief
This study suggests that subgrouping autoimmune diseases by a Traditional Chinese Medicine phenotype (Dampness ZHENG) corresponds to distinct T‑ and B‑cell receptor patterns.
For people with ulcerative colitis, that could point to new biomarker approaches for defining disease subtypes that might matter for future personalized research or therapies.
Researchers in immune profiling and biomarkers; clinicians and translational scientists working on IBD/ulcerative colitis heterogeneity; scientists interested in TCM‑guided phenotyping.
This study sequenced T‑cell and B‑cell receptor repertoires from patients with psoriasis, rheumatoid arthritis and ulcerative colitis and compared groups defined by a Traditional Chinese Medicine (TCM) phenotype called Dampness ZHENG versus non‑Dampness.
The authors report disease‑wide reductions in clonotype richness and diversity compared with healthy controls and distinct repertoire features associated with Dampness ZHENG (changes in clonotype richness, diversity indices, V‑gene usage, and TRG/TRA/TRB patterns).
They trained machine‑learning models (LASSO, GLM, OPLS‑DA) and validated a three‑V‑segment classifier that showed moderate accuracy in an independent cohort. The paper is framed as a potential way to stratify autoimmune diseases using TCM phenotypes and adaptive immune signatures; it does not test a therapy or provide clinical recommendations.
The results come from repertoire sequencing and computational analysis of 59 participants with validation in an independent cohort, as reported in the abstract.
Structured content depth: abstract. Summary and interpretations here are grounded in the article abstract; the full paper should be reviewed for methods, cohort details, and limitations before drawing clinical conclusions.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Natural Science Foundation of China, award U20A20397; National Natural Science Foundation of China, award U23A6012; Science and Technology Planning Project of Guangdong Province, award 2020B1111100005; Science and Technology Planning Project of Guangdong Province, award 2020B1111100006
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or...
Distinguishing Crohn’s from ulcerative colitis can be hard and often requires invasive tests. A reliable blood test would speed diagnosis and help patients start the right treatments sooner. This study is an early step...
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.
